4.09Open4.09Pre Close0 Volume215 Open Interest22.50Strike Price0.00Turnover82.30%IV4.56%PremiumDec 20, 2024Expiry Date2.93Intrinsic Value100Multiplier20DDays to Expiry1.16Extrinsic Value100Contract SizeAmericanOptions Type0.7715Delta0.0617Gamma6.87Leverage Ratio-0.0392Theta0.0087Rho5.30Eff Leverage0.0180Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet